ALX Oncology Holdings Inc. (NASDAQ:ALXO) Director Rekha Hemrajani Buys 30,000 Shares

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Director Rekha Hemrajani purchased 30,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were purchased at an average price of $1.55 per share, with a total value of $46,500.00. Following the completion of the transaction, the director now directly owns 33,000 shares of the company’s stock, valued at $51,150. This represents a 1,000.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

ALX Oncology Trading Up 1.0 %

ALXO traded up $0.02 during mid-day trading on Wednesday, hitting $1.57. 1,118,851 shares of the stock were exchanged, compared to its average volume of 785,839. The firm’s fifty day moving average is $1.52 and its two-hundred day moving average is $4.19. ALX Oncology Holdings Inc. has a 1-year low of $1.19 and a 1-year high of $17.83. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.07. The company has a market cap of $82.54 million, a PE ratio of -0.52 and a beta of 1.04.

Institutional Investors Weigh In On ALX Oncology

Several large investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in ALX Oncology by 4.3% during the 1st quarter. Vanguard Group Inc. now owns 1,566,464 shares of the company’s stock worth $17,466,000 after purchasing an additional 64,055 shares during the period. Marshall Wace LLP increased its holdings in ALX Oncology by 423.0% during the 2nd quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock worth $3,833,000 after purchasing an additional 514,133 shares during the period. Privium Fund Management B.V. increased its holdings in shares of ALX Oncology by 28.2% in the 3rd quarter. Privium Fund Management B.V. now owns 509,059 shares of the company’s stock valued at $926,000 after acquiring an additional 112,093 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of ALX Oncology by 87.2% in the 2nd quarter. Renaissance Technologies LLC now owns 438,200 shares of the company’s stock valued at $2,642,000 after acquiring an additional 204,100 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of ALX Oncology in the 3rd quarter valued at about $578,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Stifel Nicolaus reissued a “hold” rating and set a $3.00 price objective (down previously from $5.00) on shares of ALX Oncology in a research note on Friday, August 9th. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of ALX Oncology in a research note on Tuesday, August 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research note on Tuesday, November 12th. Finally, UBS Group lowered their price objective on ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, August 16th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $12.50.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.